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Suppression of inflammation and tissue damage by a
hookworm recombinant protein in experimental colitis
Ivana B Ferreira1, Darren A Pickering1, Sally Troy1, John Croese1,2, Alex Loukas1 and Severine Navarro1
Gastrointestinal parasites, hookworms in particular, have evolved to cause minimal harm to their hosts when present in small
numbers, allowing them to establish chronic infections for decades. They do so by creating an immunoregulatory environment
that promotes their own survival, but paradoxically also benefits the host by protecting against the onset of many inflammatory
diseases. To harness the therapeutic value of hookworms without using live parasites, we have examined the protective
properties of the recombinant protein anti-inflammatory protein (AIP)-1, secreted in abundance by hookworms within the
intestinal mucosa, in experimental colitis. Colitic inflammation assessed by weight loss, colon atrophy, oedema, ulceration and
necrosis, as well as abdominal adhesion was significantly suppressed in mice treated with a single intraperitoneal dose of AIP-1
at 1 mg kg−1. Local infiltration of inflammatory cells was also significantly reduced, with minimal goblet cell loss and preserved
mucosal architecture. Treatment with AIP-1 promoted the production of colon interleukin (IL)-10, transforming growth factor
(TGF)-β and thymic stromal lymphopoietin (TSLP), resulting in the suppression of tumour necrosis factor (TNF)-α, IL-13 and
IL-17 A cytokines and granulocyte macrophage colony-stimulating factor (GM-CSF), CX motif chemokine (CXCL)-11 and
cyclooxygenase synthase (COX)-2 mRNA transcripts. AIP-1 promoted the accumulation of regulatory T cells in the colon likely
allowing rapid healing of the colon mucosa. Hookworm recombinant AIP-1 is a novel therapeutic candidate for the treatment of
inflammatory bowel diseases that can be explored for the prevention of acute inflammatory relapses, an important cause of
colorectal cancer.
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Inflammatory bowel diseases (IBD) are a group of chronic auto-
immune diseases affecting the digestive track, primarily represented by
Crohn’s disease (CD) and ulcerative colitis (UC).1 Both types of IBD
are caused by an inappropriate immune response in genetically
susceptible individuals to intestinal microbial species, however, the
site and nature of inflammation differ between the two diseases.2,3 CD
can affect the entire intestinal track from the mouth to the anus,
whereas UC mainly affects the colon and the rectum. Although the
role of innate cells is pivotal in CD, both conditions are T-cell-
mediated and characterised by increased levels of interleukin (IL)-6,
IL-17, interferon (IFN)-γ and tumour necrosis factor (TNF)-α.4–6
However, the immune response in UC appears to be more skewed
towards a T-helper cell type 2 (Th2) response, with increased levels of
IL-4 and IL-13 production in the tissue.6 The current treatments for
IBD rely on nonspecific immunosuppressive drugs, such as steroids,
antibiotics, and immunomodulators targeting the TNF pathway or the
gut-homing integrin α4β7.7–11 However, the repetitive cycles of acute
inflammation followed by temporary remission in IBD result over
time in severe impairment of gut function, motility and tissue
remodelling.12–14 Despite encouraging clinical trial end points,
TNF-α inhibitors are not effective in all patients and do not prevent
relapse.9–11 One of the major consequences of UC progression is the
development of colorectal cancer, which is the third most common
malignancy in humans.15,16 The rising incidence of IBD parallels the
trend of other autoimmune and allergic diseases.17,18 However, for
reasons that are still unclear, the rate of childhood-onset IBD has been
the highest observed over the past two decades.19–21 In addition to the
debilitating symptoms associated with the disease, children affected by
early-onset IBD suffer significant malabsorption and nutritional
deficiencies resulting in growth failure, skeletal impairment, and
significant psychological and developmental delays.22–25 These recent
observations underscore the urgent need for novel therapeutic
approaches to be developed.
A promising new avenue of research using live helminth therapy has
seen encouraging levels of success for the management of autoimmune
diseases, such as IBD and Celiac disease.26–28 Indeed, experimental
infection with ova of the pig whipworm Trichuris suis (TSO)
successfully improved both UC and CD Disease Activity Index.29
However, because humans are not the natural host and infection
resulted in rapid parasite clearance, repeated administrations were
required30 and recent phase 2 clinical trials in IBD failed to
meet clinical end points.31 Interestingly, hookworms, such as
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Necator americanus and Ancylostoma caninum, have co-evolved with
their mammalian hosts where they establish chronic infections over
many years.28 The tolerability of iatrogenic N. americanus infection has
been assessed in patients with autoimmune gastrointestinal diseases.
Hookworm infection coupled with escalating oral gluten challenge
resulted in remarkably improved gluten tolerance in Celiac patients,32
and a non-significant trend towards reduced CD activity scores in a
small number of CD patients after hookworm infection.33
Nematodes, and hookworms in particular, have been shown to
ameliorate chronic inflammatory diseases by promoting regulatory
immune circuits, particularly the induction of regulatory T cells (Tregs)
and the modification of the intestinal microbiota.28,32,34–37 We, and
others, have shown that much of the immunomodulatory prowess of
helminths can be attributed to the release of excretory/secretory (ES)
products into host tissues.36,38–40 This complex mix of proteins41 and
other molecules (unpublished) has been shown to ameliorate colitis in
numerous mouse models,38,42,43 and denaturation of the protein
component of ES products ablated the anti-colitic properties.38
Proteomic analysis of A. caninum excretory/secretory (ES) proteins
revealed the relative abundance of two Tissue Inhibitor of Metallo-
protease (TIMP)-like proteins, anti-inflammatory protein (AIP)-1 and
AIP-2,41 neither of which appear to have the protease inhibitory
properties that characterise the TIMP family.44 We recently showed
that AIP-2 induced the expansion of Tregs that promoted long-term
protection against allergic responses in both mice and humans.40
A similar rationale was used earlier to investigate Ac-AIP-1 (also
referred to as tissue inhibitor of metalloprotease (TIMP)-1) as a
potential modulator of dendritic and T-cell function.45 However, its
efficacy as a therapeutic approach to suppress inflammatory disease
was never tested. In this study, haptenating agent 2,4,6-trinitrobenzene
sulphonic acid (TNBS) was used to evaluate the therapeutic validity
of Ac-AIP-1 for treating acute colitis. Despite its limitations, the
TNBS-model of colitis is T-cell mediated and skewed towards a Th2
phenotype comparable to human UC.46–48 Recombinant Ac-AIP-1
protected against all the hallmark parameters of inducible colitis and
promoted a regulatory immune environment in treated mice.
RESULTS
Recombinant Ac-AIP-1 protects against TNBS-induced intestinal
inflammation
The immunoregulatory properties of Ac-AIP-1 have previously been
explored using an in vitro T-cell suppression assay and protein-pulsed
bone-marrow-derived dendritic cells.45 Suppression of inflammation
using the related hookworm protein, AIP-2, was shown to be optimal
at 1 mg kg− 1 in a mouse model of asthma40 and colitis (unpublished).
Therefore, the same dose for administering AIP-1 herein was used.
To determine the therapeutic potential of AIP-1 in a model of acute
inflammation, mice were treated with 1 mg kg− 1 of AIP-1 or vehicle
via the intraperitoneal (i.p) route. Five hours later, mice were
administered 2.5 mg trinitrobenzoylsulfonic acid (TNBS) in 50%
Figure 1 Protective effects of AIP-1 against weight loss and colon damage in TNBS-induced colitis. (a–e) Mice received a single intraperitoneal injection (i.p)
of 20 μg AIP-1 in PBS or vehicle, followed 5 h later by an enema with 2.5 mg of TNBS in 50% ethanol. (a) Body weight was recorded daily for the indicated
groups. Data show means± s.e.m. of a representative experiment out of five with n=5. Two-way ANOVA with Tukey’s comparisons test used to compare
vehicle vs AIP-1 over time. (b, c) Colons were removed and measured; adhesion, oedema, mucosal wall thickening and ulceration were scored on a scale of
0–3, with three indicating highest degree of damage. (d, e) Colons were opened longitudinally, washed in PBS, and a 1 cm section from the distal colon was
fixed in 4% paraformaldehyde. Data show histological micrographs of hematoxylin and eosin-stained (H&E; top images) or periodic-acid Schiff (PAS; bottom
images) (×200) obtained from a representative mouse from each group. Histological score was performed by assessing epithelial changes (presence of goblet
cells (1), hyperplasia (2), erosion (3)), cell infiltrate (4, 5), and mucosal architecture (6). Data show means± s.e.m. of a representative experiment with n=5.
Mann–Whitney U-test performed comparing naïve vs vehicle groups (#) or vehicle vs AIP-1 groups (*); *Po0.05; **Po0.01; ***Po0.001; ****Po0.0001.
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ethanol via intrarectal injection, resulting in a 15 to 20% weight loss in
the vehicle group over the course of the study (Figure 1a). Interest-
ingly, mice treated with AIP-1 displayedo10% weight loss on the first
day post-TNBS injection, and recovered most of their initial weight by
day 3 (Figure 1a). Cellular enumeration of peritoneal lavages showed
that i.p treatment with AIP-1 did not induce eosinophil infiltration at
the site of injection (data not shown). In comparison to the naive
control mice, colon lengths were significantly decreased in the vehicle
group (Po0.0001), while AIP-1-treated mice remained unaltered by
the administration of TNBS (Figure 1b). Macroscopic analysis of the
colons revealed a significant reduction of tissue inflammation as seen
by minimal adhesion, oedema, wall thickening and ulceration
(Figure 1c). Haematoxylin and eosin (H&E) staining of distal colon
sections from the vehicle group showed mucosal erosion and epithelial
hyperplasia, pronounced cellular infiltration in the lamina propria and
intraepithelial compartments, evidence of oedema and ulceration, and
loss of healthy goblet cells (Figure 1d, top panels, Figure 1e). However,
mice treated with AIP-1 displayed an overall mucosal architecture
similar to that of healthy controls (Figures 1d and e). Mucin secretion
and goblet cell numbers following periodic acid-Schiff-alcian blue
(PAB) staining of the colons further illustrated that AIP-1 treatment
promoted the maintenance of mucosal barrier integrity (Figure 1d,
bottom panels). In contrast, vehicle-treated mice displayed a signifi-
cant decrease in mucin production, loss of goblet cells and pro-
nounced mucosal barrier remodelling (Figure 1d, bottom panels).
Together, these results show that AIP-1 is highly efficient at suppres-
sing TNBS-induced intestinal inflammation.
Production of N-glycan-deficient Ac-AIP-1
Yeast-based expression of recombinant proteins is associated with high
N-linked glycosylation, which can interfere with the immune
system.46,49–52 In addition, helminth excretory/secretory (ES) products
contain glycan moieties that have been shown to skew the immune
system, particularly towards the Th2 phenotype.52 The native AIP-1
protein sequence contains an asparagine (Asn) at position 119, which
appears to be glycosylated by Pichia (Figures 2a and b). To eliminate
addition of the N-glycan we substituted Asn-119 for glutamine (Gln),
and termed the mutant recombinant protein AIP-1Q119. SDS-PAGE
profile of AIP-1Q119 showed an absence of smearing compared to wild
type recombinant AIP-1, indicative of an absence of N-glycosylation
(Figure 2c).
AIP-1-induced protection against intestinal inflammation is
independent of yeast-derived glycan modification
To assess whether Asn-119 substitution to Gln affected the anti-
inflammatory properties of the recombinant wild type protein, mice
were treated as described previously with AIP-1Q119 (1 mg kg
− 1) or
vehicle prior to TNBS injection (Figures 3a–e). The level of protection
in AIP-1Q119-treated mice against weight loss was comparable to that
of AIP-1 (Figure 3a). Colon shortening and pathology were also
significantly inhibited with AIP-1Q119 when compared to the vehicle
control (Figures 3b and c). Finally, mucosal architecture and integrity
were maintained upon treatment in comparison to the vehicle
group as shown by the significant reduction of histology score in
AIP-1Q119-treated mice (Figures 2d and e).
Treatment with AIP-1 or AIP-1Q119 suppresses systemic
inflammation
In vitro T-cell receptor stimulation of splenocytes revealed a significant
systemic inhibition of tumour necrosis factor (TNF)-α production in
both AIP-1- and AIP-1Q119-treated mice, which correlates with the
suppression of TNBS-induced pathology observed previously
(Figure 4a). Interestingly, both recombinant proteins seemed to
restore systemic production of IL-10 to a level comparable to that
seen in healthy controls, suggesting the promotion of pro-regulatory
responses by AIP-1 (Figure 4b).
AIP-1Q119 promotes colon immune regulation and tissue repair
To address the impact of AIP-1Q119 treatment on the production of
cytokines at the site of inflammation, colons of mice exposed to TNBS
were homogenised and analysed by ELISA (Figures 5a–c). In line
with our previous observations, AIP-1Q119 treatment significantly
suppressed inflammatory cytokines IL-13, IL-17 A and IFN-γ
(Figures 5a–c). Interestingly, AIP-1Q119 administration also signifi-
cantly increased the levels of thymic stromal lymphopoietin (TSLP) in
the colon suggesting mucosal healing (Figure 5d). As seen previously
in the spleen, IL-10 production in the colon of AIP-1Q119-treated mice
was also markedly increased as well as TGF-β, suggesting the
promotion of regulatory responses (Figures 5e and f). To reveal the
potential involvement of regulatory T cells (Treg) in the protection
against TNBS-induced colitis by AIP-1Q119, colons and peripheral
tissues were collected and cells analysed by flow cytometry. While no
significant differences were seen in the peripheral tissues, colons of
mice treated with AIP-1Q119 displayed a significantly increased
frequency of CD4+CD25+Foxp3+ cells (Figure 5g).
AIP-1Q119 affects the proinflammatory processes induced by
TNBS in the colon
To reveal suppression of inflammation by AIP-1Q119 in gut tissue, total
RNA was extracted from colon sections of mice exposed to TNBS.
Differentially expressed genes were identified by comparison of
expression levels with vehicle-treated samples that served as baseline
(Figure 6). Mice treated with AIP-1Q119 displayed a significant
decrease in the expression of mRNAs in the colon encoding the
proinflammatory mediators granulocyte macrophage colony-
stimulating factor (GM-CSF)- 2, cyclooxygenase (COX)-2, IL-6 and
CXC-motif chemokine 11. Although not significant, mice treated with
AIP-1Q119 also displayed increased expression of connective tissue
growth factor (CTGF)-encoding mRNA, indicating potential enhanced
tissue repair processes. Together, this profile suggests that AIP-1Q119
affects the expression of factors responsible for the migration of
activated inflammatory cells such as neutrophils and lymphocytes,
likely contributing to the reduction of tissue damage and promoting
repair.
DISCUSSION
We38,42 have previously demonstrated that A. caninum excretory/
secretory (AcES) products significantly alleviated intestinal pathology
in a mouse model of UC. Protease digestion and heat denaturation
showed the protective compound(s) of AcES were of protein moieties.
Interestingly, despite AcES retaining characteristics of inducing Th2
cytokines, pro-regulatory and repair mechanisms were also observed.38
Indeed, proinflammatory cytokines IFN-γ, IL-6, IL-17 A and TNF-α
were dramatically suppressed, and the recruitment of alternatively
activated macrophages and IL-10/IL-4-producing cells were seen in the
mucosa. As previously, shown by Mulvenna and colleagues, AcES is a
complex mixture of over 100 proteins, the function of which remain
mostly unknown.41 Recently, one of the most abundant proteins
produced by A. caninum, AIP-2, was shown to suppress
allergen-induced inflammation both in experimental asthma and
PBMCs from confirmed allergy patients.40 AIP-2 administration
modified mesenteric dendritic cell function by enhancing
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retinaldehyde dehydrogenase activity, resulting in a significant accu-
mulation of Tregs at mucosal sites. Interestingly, A. caninum AIP-1 is
also an abundant protein found in AcES; however, its function
remains unclear. Ac-AIP-1, like Ac-AIP-2, contains a signal peptide
followed by a TIMP-like netrin domain. Ac-AIP-2 has a C-terminal
tail that appears to be absent from Ac-AIP-1 (Figure 2). Cuellar and
colleagues showed that AIP-1 induced a systemic state of T-cell
unresponsiveness as seen by ex vivo T-cell receptor (TCR) activation of
splenocytes with anti-CD3.45 The protein was further shown (in a
non-diseased state) to modulate major histocompatibility complex
(MHC)-II expression on bone-marrow-derived dendritic cells
which were capable of inducing IL-10-producing CD4 and CD8
Foxp3+ Tregs.
In this study, we have demonstrated that Ac-AIP-1 significantly
protected mice against TNBS-induced weight loss, as well as the
cardinal features of colitis. Indeed, colon mucosal barrier integrity was
maintained despite the chemical assault resulting in the absence of
colon shortening, oedema, ulceration and necrosis. A mutation on the
glycosylation site of the recombinant protein demonstrated that the
protection induced by AIP-1 was not a bystander immunomodulatory
effect of glycans added during the protein expression and folding
process in Pichia.51,52 When administered systemically in TNBS-
treated mice, both native and glycosylation mutant AIP-1 significantly
suppressed the production of IL-13, IL-17 A, IFN-γ and TNF-α,
known to play a central role in IBD.53,54 Although IL-13 is directly
implicated with increased colon epithelial permeability and apoptosis,
therapeutic intervention using IL-13 blockade, Anrukinzumab, failed
to show any improvement of clinical response or remission.55,56
Evidence undeniably supports that colitis is a multifactorial disease,
which cannot be suppressed with the neutralisation of a single
component, such as IL-13. However, inhibition of signal transducer
and activator of transcription (STAT)-6, for which the phosphoryla-
tion status is highly elevated in UC patients, seemed to prevent
IL-13-induced apoptosis and improved transepithelial resistance.57
Because of the complexity of IBD pathology, cytokine neutralisation
therapy has shown mixed results suggesting that the development of
novel treatments should focus on different targets. Indeed, the use of
Infliximab or Adalimumab, both monoclonal antibodies directed
against TNF-α, were shown to be highly effective against acute colitis,
although efficacy was strongly dependent on the severity of the
disease.58,59 In addition, resistance to anti-TNF-α therapy has been
observed over time, supporting the notion that single cytokine therapy
is insufficient for the treatment of IBD. Indeed, the suppression of
proinflammatory mediators without promoting mucosal barrier repair
will not prevent relapse and disease progression. Interestingly, despite
the short timeline of the TNBS model, AIP-1 not only suppressed key
pathogenic cytokines important to colitis, but also significantly
prevented colonic mucosal damage.
As seen previously with AcES treatment in experimental colitis,
AIP-1 promoted the production of IL-10, suggesting a potential
mechanism of systemic regulation of inflammation.38 A similar
observation was made upon analysis of the colonic mucosa in which
the levels of IL-10 were significantly elevated in comparison to vehicle-
treated mice but also in comparison with naïve control. This further
supports the notion that IL-10 production seems to be an important
suppressive mechanism induced by AIP-1. A genetic-linkage analysis
of patients with colitis revealed distinct mutations in the IL-10 gene,
demonstrating a central role for this cytokine in the negative feedback
necessary to maintain mucosal homeostasis.60,61 In our study, TGF-β
was also found to be elevated in the colonic mucosa upon AIP-1
treatment. Not only is TGF-β pivotal for the suppression of gut
inflammation and enhancing barrier function, but it also suppresses
tumour progression in colon cancer and promotes the induction of
functional Tregs from naive CD4
+ T-cell precursors.62,63 Interestingly,
treatment with AIP-1 resulted in a significant increase in the frequency
of CD4+CD25+Foxp3+ T cells in the colonic lamina propria. Together,
this data suggests that AIP-1 modulates the mucosal cytokine
environment by enhancing regulatory processes.
Despite its involvement in the development of allergy and key role
in the induction of Th2 responses, TSLP has been shown to have
protective effects in experimental colitis.64,65 The levels of TSLP in the
colon of AIP-1-treated mice were strikingly higher than both naïve
and vehicle control mice. Interestingly, TSLP was shown to be
important for protective immunity following infection with the
gastrointestinal nematode Trichuris muris by limiting Th1- and
Th17-induced mucosal damage.65–67 In addition, TSLP can induce
Foxp3+ Treg by influencing plasmacytoid dendritic cell function in
both mice and humans.68,69 AIP-1 administration modulated colon
expression of a combination of mediators involved in inflammation;
expression of mRNAs encoding GM-CSF, CXCL11, IL-6 and PGE-2
were significantly downregulated in AIP-1-treated mice in comparison
to vehicle control. Reduced expression of these particular mediators
implies that AIP-1 may affect the expansion and migration of activated
Th1/Th17 cells induced by TNBS by interfering with PGE-2/IL-6
signalling and GM-CSF/CXCL11 production.70 Although not signifi-
cant, the expression level of connective tissue growth factor (CTGF)
Figure 2 Wild type AcAIP-1 expressed in Pichia is glycosylated at Asn-119,
and mutation of Asn-119 to Gln ablates N-glycosylation of the recombinant
protein. (a) Primary sequence alignment of the mature (signal peptides
removed) sequences of AcAIP-1 and AcAIP-2. Conserved residues are shown
in red and similar substitutions are in blue. Disulfide-forming Cysteines are
in yellow boxes. N-glycosylation sites (where the Asn was substituted for Gln)
are underscored and in bold font. Note the long acidic C-terminus of AIP-2
that is absent in AIP-1. (b) The image on the left shows a SDS-
polyacrylamide gel stained with Coomassie blue showing recombinant
purified wild type AIP-1 and AIP-2 treated (+) or not (−) with PNGaseF to
remove N-glycans. Five and one microgram of each protein was loaded on
the gel. The image on the right shows recombinant AIP-1Q119 (1 μg); note
its molecular weight is similar to enzymatically deglycosylated wild type
AIP-1. Molecular weight markers (M) are shown on the left and right.
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trended towards elevated levels in AIP-1-treated mice, further
supporting cell turnover, wound healing and tissue repair.71 While
the direct action of AIP-1 on the epithelium, the production of TSLP
and the inhibition of PGE-2 has yet to be fully demonstrated,
AIP-1 seems to induce a multifactorial response beneficial for the
suppression of inflammation and tissue damage induced by TNBS.
In like fashion to our findings with AIP-2 in a mouse model of
asthma,40 AIP-1 seems to promote regulatory cells in the mucosa and
suppress inflammation.40 However, the upregulation of genes involved
in mucosal turnover observed herein for AIP-1 was not described for
AIP-2. Indeed, AIP-1 seems to have a role in modulating local and
systemic production of pro-regulatory cytokines, such as IL-10 and
TGF-β, likely allowing tissue repair. Another cytokine important for
mucosal repair in IBD is IL-22, which was significantly elevated in the
colon of human volunteers experimentally infected with human
hookworms.37 However, the involvement of IL-22 in AIP-1-induced
protection in colitis has yet to be determined. Considering that both
AIP-1 and AIP-2 are found abundantly in AcES, one can postulate that
both proteins act concertedly to increase the number of regulatory
cells and allow the tissue to rapidly heal from parasite-induced injury.
While it would be pertinent to assess the combined therapeutic role of
AIP-1 and AIP-2 in colitis, we have shown here that on its own, AIP-1
seems to be a good therapeutic candidate for the treatment of colitis by
supressing inflammatory responses, preventing tissue remodelling and
promoting gut healing.
METHODS
Mice
Five-week-old male C57BL/6 were purchased from the Animal Resources
Centre (Perth, Western Australia, Australia) and were housed according to
Australian code for the care and use of animals for scientific purposes under
specific pathogen-free conditions. Mice received food and water ad libidum. All
procedures were approved by the James Cook University Animal Ethics
Committee under projects A1484 and A2012.
Figure 3 AIP-1Q119 retains the protective properties against TNBS-induced inflammation. (a–e) Mice received a single intraperitoneal injection (i.p) of 20 μg
AIP-1Q119 in PBS or vehicle, followed 5 h later by an enema with 2.5 mg of TNBS in 50% ethanol. (a) Body weight was recorded daily for the indicated
groups. Data show means± s.e.m. of a representative experiment out of five with n=5. Two-way ANOVA with Tukey’s comparisons test used to compare
vehicle vs AIP-1Q119 over time. (b, c) Colons were removed and measured; adhesion, oedema, mucosal wall thickening and ulceration were scored on a scale
of 0–3, with 3 indicating highest degree of damage. (d, e) Colons were opened longitudinally, washed in PBS, and a 1 cm section from the distal colon was
fixed in 4% paraformaldehyde. Data show histological micrographs of periodic-acid Schiff (PAS) (×200) obtained from a representative mouse from each
group. Histological score was performed by assessing epithelial changes (presence of goblet cells (1), hyperplasia (2), erosion), cell infiltrate, and mucosal
architecture. Data show means± s.e.m. of a representative experiment out of five, with n=5. Mann–Whitney U-test performed comparing naïve vs vehicle
groups (#) or vehicle vs AIP-1Q119 groups (*); *Po0.05; **Po0.01; ***Po0.001; ****Po0.0001.
Figure 4 AIP-1 and AIP-1Q119 modulate systemic cytokine production in
TNBS-treated mice. (a, b) Culture supernatant concentrations of TNF-α and
IL-10 assessed by ELISA from splenocytes stimulated with 1 μg ml−1 α-CD3
for 3 days. Data show means± s.e.m. of a representative experiment out of
five, with n=5. Mann–Whitney U-test performed comparing naïve vs vehicle
groups (#) or vehicle vs AIP-1 or AIP-1Q119 groups (*); *Po0.05;
**Po0.01.
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Reagents and protein expression
Recombinant Ac-AIP-1 and the glycosylation mutant Ac-AIP-1Q119 were
expressed as secreted proteins in the yeast Pichia pastoris using methods
described elsewhere.72 Mutation of Asn-119 to Gln was achieved using PCR as
described elsewhere.73 The cDNAs encoding the mature sequences of Ac-AIP-1
(amino acids 17-140) and Ac-AIP-1Q119 were cloned in frame into pPICZαA
(Invitrogen, CA, USA) using XhoI and XbaI restriction sites. The recombinant
plasmids were linearized by SacI digestion and transformed into P. pastoris
strain X-33 by electroporation according to the manufacturer’s instructions
(Invitrogen). Transformants were selected on yeast extract-peptone-dextrose
plates containing zeocin and assessed for expression of recombinant protein via
western blot with monoclonal anti-6 ×His antibody. A western blot-positive
clone for each protein was grown in a shaker flask, and expression of the
recombinant 6 ×His tagged Ac-AIP-1 and Ac-AIP-1Q119 were induced with
methanol, as per the manufacturer’s instructions (Invitrogen). The recombi-
nant fusion proteins were purified with a nickel affinity column and eluates
containing Ac-AIP-1 and Ac-AIP-1Q119 were concentrated using Amicon Ultra
Centrifugal concentrators and buffer exchanged into phosphate-buffered
saline (PBS) pH 7.4. Lipopolysaccharide contents in Ac-AIP-1 and
Ac-AIP-1Q119 were below 5 ng mg
− 1 as determined by the Limulus
Amoebocyte Lysate (LAL) assay (Pierce Thermo Fisher Scientific, MA, USA).
Induction of colitis
Mice were randomly assigned to each group. Recombinant proteins were
administered via the intraperitoneal (i.p) route in sterile phosphate-buffered
saline at a dose of 1 mg kg− 1. Five hours later, mice were anaesthetised with
xylazine (5 mg kg− 1, Rompun 2%, Bayer, Germany) and ketamine
(50 mg kg− 1, Ketavest; Pfizer Inc., NY, USA). 2,4,6-Trinitrobenzenesulfonic
acid (TNBS; Sigma-Aldrich, MI, USA) was prepared by dissolving 2.5 mg in
50% ethanol. Once unresponsive, mice received an enema with a 125 mg kg− 1
dose of TNBS using a lubricated 20-G soft catheter (Terumo, Tokyo, Japan) as
previously described.47,48,74 Animals were monitored daily for weight loss and
general wellbeing over 4 days. Colitis experiments were repeated five times with
a sample size (n) of five mice per experimental group.
Figure 5 AIP-1Q119 induces a pro-regulatory environment in the colon of mice exposed to TNBS. (a–f) Concentrations of IFN-γ, IL-10, IL-13, IL-17 A, TGF-β
and TSLP assessed by ELISA on colon lysates. Data show means± s.e.m. of a representative experiment out of five, with n=5. Mann–Whitney U-test
performed comparing naïve vs vehicle groups (#), naive vs AIP-1Q119 groups (+), or vehicle vs AIP-1Q119 groups (*); *Po0.05; **Po0.01. (g) Naive mice
were treated with daily intraperitoneal injections of 20 μg AIP-1Q119 for 4 days, indicated tissues were collected 24 h after the last injection, and prepared
for flow cytometry analysis. SPL, Spleen; MLN, mesenteric lymph nodes; PLN, peripheral lymph nodes (popliteal, inguinal and brachial); cLP, colon lamina
propria. Data show the frequency of Foxp3-expressing cells among CD4+CD25+ cells for individual mice from a representative experiment with n=9–10 out
of 2. Mann–Whitney U-test performed comparing vehicle vs AIP-1Q119 groups (*); NS, non-significant; **Po0.01.
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Clinical assessment of colitis
To eliminate bias, mice were assessed in a blinded fashion and de-identified at
end point. Mice were weighed daily, and their overall appearance (piloerection),
activity level and posture were recorded. No animals were excluded from the
study. On day 3 following TNBS injection, mice were killed by CO2
asphyxiation, and colons were collected for observation, characterisation by
flow cytometry, cytokine measurements and RNA extraction. When dissecting,
the level of tissue adhesion was scored from 0 to 3, with 0 corresponding to
absence of adhesion and 3 corresponding to severe adhesion. Colons were
measured, cut longitudinally, washed in saline, and observed under an Olympus
SZ61 microscope (Notting Hill, VIC, Australia) (×0.67–4.5). Scoring of clinical
pathology included adhesions (0–3), mucosal oedema (0–3), ulceration (0–3)
and bowel wall thickening (0–3), for a maximum total score of 12 as previously
described.38
Tissue preparation and cell culture
Mesenteric lymph nodes (MLN), peripheral lymph nodes (brachial, inguinal,
and popliteal) (PLN), spleens and colons were processed in RPMI 1640 media
containing 2% foetal bovine serum (FBS), 400 U type I collagenase and
1 mg ml− 1 DNase I (Life Technologies, Thermo Fisher Scientific, MA, USA)
using GentleMACS (Miltenyi Biotec, Germany) and incubated for 15 min at
37 °C. Cells were strained through a 70 μm cell strainer (BD Biosciences, NJ,
USA). Erythrocytes were lysed with red blood cell lysis buffer (ACK). Colon
lamina propria (cLP) were obtained after digestion in RPMI containing 5%
FCS, 5 mM EDTA, and 2 mM dithiothreitol (DTT) as described previously.75
Briefly, colons were washed in ice-cold PBS, minced and incubated under
agitation for 30 min at room temperature. Intestinal epithelial lymphocytes
were discarded by filtration and the remainder was further incubated in RPMI
containing 5% FBS, 400 U type I collagenase and 1 mg ml− 1 DNAse I for
30 min at 37 °C. Cells were filtered and stained with anti-mouse CD3, CD4,
CD25 and Foxp3 monoclonal antibodies (BD Biosciences, eBiosciences Thermo
Fisher Scientific) and analysed on a BD FACSCanto II flow cytometer. Treg
enumeration experiments in which naïve mice were treated with a daily i.p
injection of AIP-1Q119 or vehicle for 5 days were repeated twice with a sample
size (n) of nine mice (vehicle) and ten mice (AIP-1Q119).
Histology
Distal colons were collected on day 3 post-TNBS injection and fixed overnight
in 4% paraformaldehyde, dehydrated with 70% ethanol and embedded in
paraffin. Sections were stained with haematoxylin and eosin (H&E) for
morphology or periodic acid Schiff for detection of mucopolysaccharide
accumulation as described previously.76
Cytokine quantification
Splenocytes were cultured in triplicate in flat-bottom 96-well plates (106 cells
per well) either with complete RPMI 1640 medium alone or in medium
supplemented with 1 μg ml− 1 anti-CD3 antibody (BD Biosciences) for 72 h at
37 °C and 5% CO2. Colon samples were homogenized in calcium- and
magnesium-free Hank’s Balanced Salt Solution and phosphatase and protease
inhibitor cocktail (Roche, Basel, Switzerland). IFN-γ, TNF-α, IL-10, TGF-β
(latent and active form), TSLP, IL-13 and IL-17 A were quantified by ELISA
(BD Biosciences) from splenocyte supernatants and colon homogenates.
RNA extraction and gene array
A colon section (0.5 cm) was washed in PBS, placed in 1 ml of TRIzol and
dissociated using a TissueLyser (Qiagen, Hilden, Germany) for 10 min with the
use of metal beads. Total RNA extraction was performed by phenol–chloroform
separation according to the manufacturer’s instructions. After treatment of RNA
with RQ1 DNase (Promega, WI, USA), first-strand cDNA was produced with
random hexamers and SuperScript III reverse transcriptase (Invitrogen).
Samples were tested in 1:100 dilution using a custom wound healing RT2
profiler PCR array and SYBR green (Qiagen). A Rotor-Gene 6000 (Qiagen) was
used for real-time thermal cycling. Melting curve analysis was used to confirm
that single products had been amplified. All genes were normalised for levels of
transcription relative to the housekeeping genes beta-glucuronidase (Gusb),
Hypoxanthine guanine phosphoribosyl transferase (Hprt), Glyceraldehyde-3-
phosphate dehydrogenase (Gapdh) and beta-actin Actb.
Statistical analyses
All data were analysed with GraphPad Prism (version 7; San Diego, CA, USA).
Sample size (n= 5) was determined by using a power of 80%, one-sided test,
representing the probability of finding significant differences between vehicle
and AIP-1 or AIP-1Q119-treated groups, with an acceptable Type 1 error of 0.05
and an expected effect size of 1.8. Data are expressed as the mean± s.e.m. Body
weight values were analysed using two-way analysis of variance (ANOVA)
followed by the Tukey’s post-hoc test. Comparisons for all pairs were performed
by unpaired two-tailed Mann–Whitney U-test. Significance levels were set at a
P value of 0.05.
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Figure 6 AIP-1Q119 modulates colon gene expression profile in TNBS-
exposed mice. Total medial colon mRNA transcript levels of 10 inflammatory
genes were measured at day 4. Data show the average relative gene
expression levels (2ΔΔCT) of AIP-1Q119-treated mice compared to vehicle,
with n=5. A 2ΔΔCT of 1 representing no change in expression level (dotted
line). Mann–Whitney U-test was used to determine statistical significance
compared with the vehicle group. *Po0.05.
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